Monopar

About:

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.

Top Investors: RA Capital Management, Janus Henderson Investors

Description:

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds. Its lead compound, Hu-ATN-658, is a novel monoclonal antibody for the potential treatment of several deadly cancers. Hu-ATN-658 targets the urokinase plasminogen activator receptor (uPAR). Cancer Research UK will be conducting Hu-ATN-658’s early development, including a Phase I clinical trial. In 2014, Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar founded the company in Wilmette, Illinois.

Total Funding Amount:

$21.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Wilmette, Illinois, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)monopartherapeutics.com

Founders:

Andrew Mazar, Chandler Robinson, Christopher M. Starr

Number of Employees:

11-50

Last Funding Date:

2024-10-28

IPO Status:

Public

Industries: